^
Association details:
| Biomarker: | ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of Yifei Sanjie Recipe combined with anlotinib in the treatment of the second line or above IIIB-IVB non-small cell lung cancer patients: a pilot study
Excerpt:
...Patients with negative driver genes who have received at least one type of systemic chemotherapy (including combined immune checkpoint inhibitors or anti-vascular drug therapy) have progressed, relapsed, or become intolerable; Patients with positive driver gene (EGFR mutation or ALK fusion positive) who have progressed, relapsed, or become intolerable after receiving corresponding standard targeted drug therapy; 3. ...
Trial ID:
Source:
Title:
1376P - Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial
Published date:
09/14/2020
Excerpt:
Advanced NSCLC patients progressed during or after platinum-based doublet chemotherapy were assigned to treat with docetaxel at a dose of 60mg per square meter of body-surface area and anlotinib at a dose of 12mg oral per day...4 (16.0%) patients harbored with EGFR mutation or ALK fusion...PFS was 4.5 months (95% CI, 3.5-5.5). The ORR was 7/20(35.0%), stable disease was 12/20(60.0%), DCR was 19/20(95.0%) and progress disease was 1/20(5.0%).
Secondary therapy:
docetaxel
